Cost-Effectiveness of Nintedanib for Patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD).
Lotte WesterinkJelmer Lennart Jens NicolaiMaarten Jacobus PostmaJob Frank Martien van BovenCornelis BoersmaPublished in: PharmacoEconomics - open (2022)
Long-term treatment with nintedanib could result in considerable health gains for patients with PF-ILD and can be considered cost-effective under the common willingness-to-pay threshold.